医学
肺癌
耐受性
内科学
肿瘤科
实体瘤疗效评价标准
生物标志物
临床试验
代理终结点
临床研究阶段
药效学
白细胞
疾病
循环肿瘤细胞
临床终点
癌症
呼吸道疾病
血小板
肺
进行性疾病
完全响应
化疗
液体活检
不利影响
免疫学
作者
Melissa Lynne Johnson,Giulia Fabbri,Carmela Ciardullo,Judy S. Wang,Gerald Steven Falchook,Suzanne Fields Jones,Donald K. Strickland,Jacob M. Sands,Carl Michael Gay,Robert J. Cardnell,Luis Tobalina,Sophie E. Willis,Jaime Rodriguez‐Canales,Myria Nikolaou,Emma V. Jones,Stein J. Schalkwijk,Liz Sainsbury,Alexander MacDonald,Philip Overend,Caroline Kennedy
标识
DOI:10.1038/s41416-026-03414-0
摘要
BACKGROUND: Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung cancer (SCLC). Here we report the dose-expansion results. METHODS: Eligible patients received nanoparticle-formulated AZD2811 500 mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8). Dose-expansion endpoints included: preliminary antitumour activity, safety/tolerability, pharmacokinetics, and biomarker-based disease monitoring. RESULTS: One of 21 enrolled patients achieved a partial response for an objective response rate of 4.8%; stable disease ≥6 weeks was observed in 10 patients (47.6%). The most common AZD2811-related AEs were decreased neutrophil and white blood cell count, anaemia, and decreased platelet count; grade ≥3 AZD2811-related AEs occurred in 15/21 patients. Baseline ctDNA levels were prognostic, and on-treatment ctDNA changes mirrored clinical response and identified progression early, suggesting it could be an effective surrogate for tumour tissue. Molecular profiling of paired tumour biopsies demonstrated AZD2811 pharmacodynamic activity and identified genes/pathways potentially linked to response. CONCLUSION: A personalised surveillance strategy may provide a novel avenue to monitor SCLC, supporting further investigation and potential broader clinical application. CLINICAL TRIAL REGISTRATION: NCT02579226.
科研通智能强力驱动
Strongly Powered by AbleSci AI